Apogee Therapeutics, Inc.

NasdaqGM:APGE Stock Report

Market Cap: US$10.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Apogee Therapeutics Management

Management criteria checks 4/4

Apogee Therapeutics' CEO is Michael Henderson, appointed in Sep 2022, has a tenure of 3.25 years. total yearly compensation is $1.29M, comprised of 54.2% salary and 45.8% bonuses, including company stock and options. directly owns 1.22% of the company’s shares, worth $124.40M. The average tenure of the management team and the board of directors is 3.7 years and 3.3 years respectively.

Key information

Michael Henderson

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage54.20%
CEO tenure4yrs
CEO ownership1.2%
Management average tenure3.7yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 22

AbbVie: Why The Pharma Wins Twice With Its Apogee Acquisition

Summary AbbVie Inc. acquires Apogee Therapeutics, Inc. for ~$10.9bn to bolster its late-stage immunology pipeline, targeting atopic dermatitis with best-in-class potential. Zumilokibart (APG777) offers potentially superior efficacy and dramatically reduced dosing frequency versus Dupixent and Ebglyss, positioning ABBV for strong market share capture. Phase 3 data for zumilokibart are expected by 2028, I estimate, with approval likely around 2029; risks remain if pivotal studies disappoint. I view ABBV as 15–20% undervalued, with the Apogee deal supporting a path to $90bn+ annual revenues and further upside by 2030–2035. Read the full article on Seeking Alpha
Seeking Alpha • Apr 14

Apogee Therapeutics: Engineering Biologic Dominance

Summary Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious pipeline development in inflammatory diseases. Significant R&D investments in lead IL-13 inhibitor APG777 and combination therapies reflect a strategic push for differentiated, best-in-class treatments in atopic dermatitis and asthma. Encouraging Phase 1 data for OX40L inhibitor APG990 supports its combination potential with APG777, promising infrequent dosing and broad efficacy in inflammatory diseases. Apogee targets a multi-billion dollar market with differentiated biologics, aiming for significant market share in atopic dermatitis, asthma, and eosinophilic esophagitis. Read the full article on Seeking Alpha
Seeking Alpha • Nov 10

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Summary Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD, and psoriasis. APGE's investigational pipeline includes APG808 and APG990, targeting different inflammatory pathways, enhancing its potential in the I&I market. APGE's strong cash runway and multiple upcoming catalysts, including Phase 2 results for APG777, justify its current valuation premium. Thus, despite its inherent risks, APGE's promising drug candidates and aggregate TAM make it a speculative "Buy" ahead of its upcoming earnings report. Read the full article on Seeking Alpha
Seeking Alpha • Jun 18

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

Summary Apogee Therapeutics stock has declined by 34% since a previous recommendation to buy, while the S&P 500 is up 7.7%. Apogee Therapeutics raised $420 million at $62/share, expanding their financial runway while advancing APG777 into Phase 2 trials. APG777, targeting atopic dermatitis and asthma, shows promise with less frequent dosing, aiming to compete with Sanofi's Dupixent. I recommend buying APGE stock, focusing on a barbell strategy to manage risks and capitalize on potential high returns. Read the full article on Seeking Alpha
Seeking Alpha • Mar 05

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management

Summary Apogee Therapeutics' APG777 shows promising Phase 1 results for AD, with a notably long half-life potentially reducing dosing frequency. APG777's efficacy and safety profiles justify Phase 2 trials, aiming to outperform competitors like Sanofi's Dupixent by offering less frequent dosing. Apogee boasts a strong liquidity position, with a cash runway of around 64 months, indicating minimal short-term financing needs. Recommendation: Buy APGE stock for its innovative approach and solid financials, but consider gradual investment to mitigate inherent biotech risks. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Michael Henderson's remuneration changed compared to Apogee Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$294m

Mar 31 2026n/an/a

-US$275m

Dec 31 2025US$1mUS$700k

-US$256m

Sep 30 2025n/an/a

-US$254m

Jun 30 2025n/an/a

-US$238m

Mar 31 2025n/an/a

-US$205m

Dec 31 2024US$13mUS$662k

-US$182m

Sep 30 2024n/an/a

-US$147m

Jun 30 2024n/an/a

-US$118m

Mar 31 2024n/an/a

-US$104m

Dec 31 2023US$9mUS$565k

-US$84m

Sep 30 2023n/an/a

-US$70m

Jun 30 2023n/an/a

-US$69m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$6mUS$146k

-US$43m

Compensation vs Market: Michael's total compensation ($USD1.29M) is below average for companies of similar size in the US market ($USD14.68M).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.

CEO

Michael Henderson (37 yo)

4yrs
Tenure
US$1,291,500
Compensation

Dr. Michael Thomas Henderson, M.D. serves as Chief Executive Officer at Apogee Therapeutics, Inc. since September 2022 and is its Director since June 2023. He had been Chief Business Officer of BridgeBio P...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Henderson
CEO & Director4yrsUS$1.29m1.22%
$ 124.4m
Jane Pritchett Henderson
Chief Financial Officer3.7yrsUS$855.90k0.21%
$ 21.4m
Carl Dambkowski
Chief Medical Officer4yrsUS$855.90k0.19%
$ 19.3m
Noel Kurdi
Vice President of Investor Relations3.2yrsno datano data
Matthew Batters
Chief Legal Officer & Corporate Secretary3.1yrsno datano data
Emily Cox
Senior VP & Head of People3.8yrsno datano data
Rebecca Dabora
Chief Development Officer2.4yrsno datano data
Wendy Aspden-Curran
Senior Vice President of Clinical Operations3.7yrsno datano data
Drew Badger
Senior VP and Head of Regulatory Affairs & Toxicology3.9yrsno datano data
Monica Forbes
Senior Vice President of Finance3.3yrsno datano data
Mehrak Kiankarimi
Senior Vice President of Program & Portfoliono datano datano data
Dan Mulreany
Chief Business Officerno datano datano data
3.7yrs
Average Tenure
50yo
Average Age

Experienced Management: APGE's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Henderson
CEO & Director3.3yrsUS$1.29m1.22%
$ 124.4m
Jennifer Fox
Independent Director3.3yrsUS$464.03k0.035%
$ 3.5m
William Jones
Independent Director3.3yrsUS$455.41k0.035%
$ 3.5m
Nimish Shah
Independent Director4.7yrsUS$444.53k0%
$ 0
Tomas Kiselak
Independent Director4.7yrsUS$439.99k0.068%
$ 6.9m
Mark McKenna
Independent Chairman of the Board3.1yrsUS$487.22k0.027%
$ 2.7m
Lisa Bollinger
Independent Director2.3yrsUS$444.53k0%
$ 0
3.3yrs
Average Tenure
48yo
Average Age

Experienced Board: APGE's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/02 22:26
End of Day Share Price 2026/09/02 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Apogee Therapeutics, Inc. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Julian HarrisonBTIG
Edward NashCanaccord Genuity